Catalyst Dossier · compiled by CeliA 🧫
Bristol-Myers Squibb Company (BMY)
Pharmaceutical Preparations · market cap $110.3B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-31 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Bristol-Myers Squibb (BMY) is a large-cap pharmaceutical company with ~$115.8B market cap, anchored by Eliquis (30% of 2025 revenue), Opdivo (21%), and Orencia (8%). The company generated $48.2B in 2025 revenue with $7.1B net income, but carries a heavy $36.9B net debt load, reflecting prior M&A activity. Key near-term catalysts include a Phase 3 readout for KarXT (November 2026, imp 9/10) and Ipilimumab (March 2027, imp 9/10), alongside a PDUFA decision for Camzyos in May 2027.
The catalyst path
- 2026-12-31 (est.)Phase 3imp 7/10
- 2026-12-31 (est.)Phase 2 · Nivolumab 40 mg in 4 ml Injectionimp 7/10
- 2027-07-16 (est.)Phase 2 · Luspaterceptimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Arlocabtagene Autoleucel | Phase 2 | Multiple Myeloma |
| CC-97540 | Phase 2 | Lupus Erythematosus, Systemic |
| Vinflunine | Phase 3 | Bladder Cancer |
| BMS-936558 (Nivolumab) | Phase 3 | Melanoma |
| DCV/ASV/BMS-791325 | Phase 3 | Hepatitis C |
| adefovir | Phase 3 | Hepatitis B |
| peginterferon alfa-2a | Phase 2 | Hepatitis C Virus |
| BMS-986489 (BMS-986012+Nivolumab) | Phase 3 | Extensive-Stage Small Cell Lung Cancer |
| BMS-650032 | Phase 2 | Chronic Hepatitis C |
| Ozanimod | Phase 3 | Colitis, Ulcerative |
| Irbesartan | Phase 3 | Congestive Heart Failure |
| Deucravacitinib | Phase 3 | Plaque Psoriasis |
| MDX-010 | Phase 2 | Prostate Cancer |
| stavudine extended-release, lamivudine, efavirenz | Phase 3 | HIV Infections |
| paclitaxel (PTX) | Phase 3 | Breast Cancer |
| BMS-986177 | Phase 2 | Acute Ischemic Stroke |
| BMS-790052 (Daclatasvir) | Phase 3 | Hepatitis C |
| Entecavir (ETV) | Phase 3 | Hepatitis B |
| Relatlimab | Phase 3 | Lymphoma, Non-Hodgkin |
| BMS-790052 | Phase 2 | Hepatitis C Infection |
Price & technical context
3-month
+13.4%
6-month
+6.4%
12-month
+33.4%
52-wk range
$42.60–$65.89
vs 50-day MA
+8.2%
vs 200-day MA
+14.0%
Realized vol
27.5%
Max drawdown
-32.5%
Daily closes through 2026-08-17. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BMY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.